Remove Diabetes Remove Kidney Disease Remove Strokes
article thumbnail

SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.

article thumbnail

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Medical Xpress - Cardiology

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

article thumbnail

Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database

Cardiovascular Diabetology

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.

article thumbnail

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

Science Daily - Heart Disease

New research shows sotagliflozin is the only drug in its class to demonstrate these results.

article thumbnail

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Cardiovascular Diabetology

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

article thumbnail

Abstract WP278: Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page AWP278-AWP278, February 1, 2024. Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE.

article thumbnail

Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial

Circulation

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among